Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | CDC42 | P60953 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RB1 | P06400 | 3/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16433458 | 0.89 | CYP2D6 (0.67) | CYP2D6KCNH2DHODHCDC42GAA | |
| SCHEMBL4139855 | 0.84 | CYP2D6 (1.00) | CYP2D6KCNH2DHODHCDC42GAA | |
| SCHEMBL4156971 | 0.83 | CYP2D6 (0.78) | CYP2D6KCNH2DHODHCDC42MAPT | |
| SCHEMBL4156182 | 0.83 | CYP2D6 (0.78) | CYP2D6KCNH2DHODHCDC42GAA | |
| SCHEMBL16433446 | 0.83 | CYP2D6 (0.78) | CYP2D6KCNH2DHODHCDC42GAA | |
| Hydrochloric Acid SCHEMBL4137980 | 0.83 | CYP2D6 (0.98) | CYP2D6KCNH2DHODHCDC42GAA | |
| SCHEMBL4142710 | 0.81 | CYP2D6 (0.73) | CYP2D6KCNH2DHODHCDC42GAA | |
| SCHEMBL4162098 | 0.81 | CYP2D6 (0.93) | CYP2D6KCNH2DHODHCDC42GAA | |
| SCHEMBL22135775 | 0.79 | CYP2D6 (0.58) | CYP2D6KCNH2DHODHCDC42GAA | |
| SCHEMBL22135774 | 0.79 | CYP2D6 (0.58) | CYP2D6KCNH2DHODHCDC42GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | VEGFA, FLT4, KDR | CYP2D6 4677/4885KCNH2 4634/4885DHODH 668/4885 |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | VEGFA, FLT4, KDR | CYP2D6 4677/4885KCNH2 4634/4885DHODH 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.